Home | About us | Editorial board | Search | Ahead of print | Current issue | Archives | Submit article | Instructions | Subscribe | Contacts | Advertise | Login 
Search Article 
Advanced search 
  Users Online: 512 Home Print this page Email this page Small font sizeDefault font sizeIncrease font size  

    Article Cited by others


Sodium-glucose cotransporter 2 inhibition and health benefits: The Robin Hood effect

Kalra Sanjay, Jain Arpit, Ved Jignesh, Unnikrishnan A G

Year : 2016| Volume: 20| Issue : 5 | Page no: 725-729

   This article has been cited by
1 Cardiorenal Syndrome in Type 2 Diabetes Mellitus – Rational Use of Sodium–glucose Cotransporter-2 Inhibitors
Sanjay Kalra,Hasan Aydin,Manisha Sahay,Sujoy Ghosh,Sundeep Ruder,Mangesh Tiwaskar,Gary Kilov,Kamal Kishor,Tiny Nair,Vikas Makkar,Ambika Gopalakrishnan Unnikrishnan,Dinesh Dhanda,Nikhil Gupta,Bharath Srinivasan,Amit Kumar
European Endocrinology. 2020; 16(2): 113
[Pubmed]  [Google Scholar] [DOI]
2 Are SGLT-2 Inhibitors the Future of Heart Failure Treatment? The EMPEROR-Preserved and EMPEROR-Reduced Trials
David M. Williams,Marc Evans
Diabetes Therapy. 2020; 11(9): 1925
[Pubmed]  [Google Scholar] [DOI]
3 A Case of Diabetic Ketoacidosis in a Patient on an SGLT2 Inhibitor and a Ketogenic Diet: A Critical Trio Not to Be Missed
Samantha Steinmetz-Wood,Matthew Gilbert,Katherine Menson
Case Reports in Endocrinology. 2020; 2020: 1
[Pubmed]  [Google Scholar] [DOI]
4 Sodium Glucose Co-Transporter 2 Inhibition Does Not Favorably Modify the Physiological Responses to Dietary Counselling in Diabetes-Free, Sedentary Overweight and Obese Adult Humans
Shane P.P. Ryan,Alissa A. Newman,Jessie R. Wilburn,Lauren D. Rhoades,S. Raj J. Trikha,Ellen C. Godwin,Hayden M. Schoenberg,Micah L. Battson,Taylor R. Ewell,Gary J. Luckasen,Laurie M. Biela,Christopher L. Melby,Christopher Bell
Nutrients. 2020; 12(2): 510
[Pubmed]  [Google Scholar] [DOI]
5 Metabolic Acidosis and its Predisposing Factor: Euglycemic Ketoacidosis Caused by Empagliflozin and Low-Carbohydrate Ketogenic Diet in Type 2 Diabetes Mellitus. Case Report
Aqsa Khan,Kamran Mushtaq,Maria Khakwani,Muhammad Shahzeb Khan Khakwani,Rizwan Mushtaq,Ross Robison,Ahsan Wahab
SN Comprehensive Clinical Medicine. 2020;
[Pubmed]  [Google Scholar] [DOI]
6 Vasculo-metabolic Axis in Type 2 Diabetes Mellitus—Abductive Reasoning from Sodium-glucose Cotransporter 2-inhibitor Evidence
Jignesh Ved,Kumardeep Paul,Sanjay Kalra
US Endocrinology. 2019; 15(1): 27
[Pubmed]  [Google Scholar] [DOI]
7 Neuromodulatory effects of anti-diabetes medications: a mechanistic review
Habib Yaribeygi,Milad Ashrafizadeh,Neil C. Henney,Thozhukat Sathyapalan,Tannaz Jamialahmadi,Amirhossein Sahebkar
Pharmacological Research. 2019; : 104611
[Pubmed]  [Google Scholar] [DOI]
8 Metformin + Sodium-glucose Co-transporter-2 Inhibitor: Salutogenic Lifestyle Mimetics in a Tablet?
Sanjay Kalra,Jubbin Jacob,ManashP Baruah
Indian Journal of Endocrinology and Metabolism. 2018; 22(1): 164
[Pubmed]  [Google Scholar] [DOI]
9 Heart Failure With Preserved Ejection Fraction in Diabetes: Mechanisms and Management
Patrick Meagher,Mohamed Adam,Robert Civitarese,Antoinette Bugyei-Twum,Kim A. Connelly
Canadian Journal of Cardiology. 2018;
[Pubmed]  [Google Scholar] [DOI]
10 Ketosis and Ketoacidosis: They May Be Sisters, but They’re Certainly Not Twins
Julie Stefanski
AADE in Practice. 2018; 6(6): 18
[Pubmed]  [Google Scholar] [DOI]
11 SGLT2-inhibitors in type-2 diabetes: The remaining questions!
Rajesh Rajput,Jignesh Ved
Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017;
[Pubmed]  [Google Scholar] [DOI]
12 Follow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
Sanjay Kalra
Diabetes Therapy. 2016; 7(4): 601
[Pubmed]  [Google Scholar] [DOI]


Read this article